Breaking News Instant updates and real-time market news.

TWTR

Twitter

$20.33

-4.5362 (-18.24%)

, DIS

Disney

$93.15

0.695 (0.75%)

12:10
10/06/16
10/06
12:10
10/06/16
12:10

On The Fly: Top stock stories at midday

Stocks opened in negative territory and remained there throughout the morning, though the averages have moved off their lows and turned mixed, with the S&P now inching into positive territory, following a report that the Vice President of the European Central Bank has disputed a prior report that the ECB was near a consensus on tapering its bond buying efforts. Investors appear willing to wait on the sidelines for tomorrow's monthly jobs data, which is scheduled for release prior to the open. ECONOMIC NEWS: In the U.S., jobless claims dropped by 5,000 to 249,000 in the week ended October 1, versus consensus expectations for 256,000 first-time claims. Gas inventories showed an 80 billion cubic feet build, above the consensus forecast for a 73 billion cubic feet build. In Europe, German factory orders increased 1% in August, boosted by domestic demand and new orders from the Eurozone. Additionally, reports indicated that Vitor Manuel Ribeiro Constancio, the VP of the European Central Bank, has disputed a prior report that the ECB was near a consensus on tapering its bond buying efforts. Reportedly Constancio said that QE will be ongoing until inflation is back on a path to the ECB's target. COMPANY NEWS: Shares of Twitter (TWTR) have dropped more than 18% near noon after Recode reported that three major companies would likely not purchase the microblog service operator - namely Walt Disney (DIS), Alphabet (GOOG; GOOGL) and Apple (AAPL). Salesforce (CRM) is said to continue to be interested in the company, and CNBC's David Faber says other suitors are considering bids as well. Meanwhile, Salesforce's shares have advanced more than 4% this morning, gaining back part of yesterday's losses... Also lower was Wal-Mart (WMT), which has slipped more than 2% after the company tempered its profit forecast for the next two fiscal years due to investments in its online business. Additionally, the world's largest retailer said store openings would slow... Yum! Brands (YUM) was also sliding near noon after the owner of KFC, Pizza Hut and Taco Bell missed Wall Street's quarterly earnings and sales expectations. The fast-food giant also reported a drop in sales in China as it prepares to spin off its business in the country. MAJOR MOVERS: Among the notable gainers was Zumiez (ZUMZ), which advanced over 16% after the company reported its September same-store sales grew 6.3% and raised its third quarter earnings outlook. The shares of the teen apparel and accessories retailer were upgraded this morning at B. Riley and at William Blair following the announcement. Also higher was ICU Medical (ICUI), which gained more than 14% after the company and Pfizer (PFE) announced that they have entered into a definitive agreement under which the former will acquire all of Pfizer's global infusion therapy business, Hospira Infusion Systems, for $1B in cash and stock. Under the terms of the agreement, Pfizer will receive approximately $400M in newly issued shares of ICU Medical, resulting in Pfizer owning approximately 16.6% of ICU upon completion of the deal. Among the noteworthy losers was Alnylam Pharmaceuticals (ALNY), which plunged 47% after the company said it will discontinue development of Revusiran for the treatment of Familial Amyloid Cardiomyopathy. The stock has been downgraded by multiple Wall Street research firms following the news. Medicines Company (MDCO), which is partnered with Alnylam on the ALN-PCSsc program, is also down over 11% near noon as well. Also lower was Tutor Perini (TPC), which slid about 7% after short-seller Carson Block disclosed yesterday at the Sohn San Francisco Investment Conference that he is placing a bet against the stock. INDEXES: Near midday, the Dow was down 11.23, or 0.06%, to 18,269.80, the Nasdaq was down 5.55, or 0.1%, to 5,310.47, and the S&P 500 was up 1.25, or 0.06%, to 2,160.98.

TWTR

Twitter

$20.33

-4.5362 (-18.24%)

DIS

Disney

$93.15

0.695 (0.75%)

CRM

Salesforce

$71.08

2.655 (3.88%)

WMT

Wal-Mart

$69.96

-1.715 (-2.39%)

AAPL

Apple

$113.05

0.05 (0.04%)

GOOG

Alphabet

$776.47

0.04 (0.01%)

GOOGL

Alphabet Class A

$801.23

-1.56 (-0.19%)

YUM

Yum! Brands

$87.31

-1.3082 (-1.48%)

ZUMZ

Zumiez

$18.27

-0.19 (-1.03%)

ICUI

ICU Medical

$125.96

0.26 (0.21%)

PFE

Pfizer

$33.70

-0.2 (-0.59%)

ALNY

Alnylam

$70.30

1.73 (2.52%)

MDCO

The Medicines Co.

$38.51

0.32 (0.84%)

TPC

Tutor Perini

$20.39

-1.81 (-8.15%)

  • 06

    Oct

  • 07

    Oct

  • 11

    Oct

  • 14

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 01

    Nov

  • 06

    Nov

  • 10

    Nov

  • 10

    Nov

  • 17

    Nov

  • 30

    Nov

  • 15

    Jan

  • 13

    Mar

TWTR Twitter
$20.33

-4.5362 (-18.24%)

10/06/16
ROTH
10/06/16
NO CHANGE
Target $103
ROTH
Buy
Salesforce should be bought on pullback, says Roth Capital
Roth Capital analyst Richard Baldry says Salesforce's (CRM) shares are down roughly 20% from their recent highs, pressured by rumors of a potential bid for Twitter (TWTR) and a recent revenue guidance increase for the second half of 2017 that was back-end loaded enough to leave his Q3 forecast lowered. However, the analyst believes the pullback offers investors an attractive entry point and advocates buying on weakness. Baldry reiterates a Buy rating and $103 price target on Salesforce's shares given the company's strong fundamentals and sector dominance.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Salesforce shares should rebound with no Twitter deal, says Cowen
Cowen analyst J.Derrick Wood expects shares of Salesforce (CRM) to rebound if the company does not buy Twitter (TWTR), which he believes will not happen. The analyst believes investors will return to fundamentals and the analyst believes upside momentum in Salesforce's core business will return in Q3. Wood reiterated his Outperform rating and $100 price target on Salesforce shares.
10/06/16
BARD
10/06/16
NO CHANGE
Target $90
BARD
Outperform
Salesforce shares should be bought, says Baird
Baird analyst Steven Ashley noted that Salesforce (CRM) CEO Mark Benioff said his company has all the customer data it needs, which he reads as meaning it would not need to make an acquisition of Twitter (TWTR) purely for data. The analyst also said the company's board is acutely aware of their responsibility to shareholders when it comes to Salesforce's stock and the potential negative impact on shares that a Twitter deal could pose. Ashley reiterated his Outperform rating and $90 price target on Salesforce shares.
10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
DIS Disney
$93.15

0.695 (0.75%)

10/06/16
SBSH
10/06/16
NO CHANGE
Target $89
SBSH
Buy
Citi says Salesforce buying Twitter 'nearly impossible' above $28/share
Citi analyst Walter Pritchard believes a Salesforce (CRM) acquisition of Twitter (TWTR) is possible financially but that such a deal would put "significant constraints" on the company for the next three-plus years. The analyst sees "very little reason" for Salesforce to own Twitter and feels the acquisition "would pose a difficult decision" for CEO Marc Benioff and the board. Salesforce closed yesterday down 6%, or $4.21, to $68.42. Recode reported last night that the company is likely the only bidder left for Twitter after Disney (DIS) and Alphabet (GOOG) opted not to pursue a deal while Apple (AAPL) is unlikely. Twitter in pre-market trading is down 14% to $21.50. In order for Salesforce to avoid a shareholder vote, it would have to borrow $7.5B to fund the transaction if Twitter were valued at $20B, or $27.50-$28 per share, Pritchard tells investors in a research note. This is a level that likely constrains the company with little additional borrowing capacity for other deals, the analyst contends. He thinks the deal is "nearly impossible to do" for Salesforce should the bidding for Twitter go above $20B or $28 per share. Pritchard has a Buy rating on Salesforce with an $89 price target.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $16
SBSH
Neutral
Citi sees 40% downside in Twitter with no takeover bid
Citi analyst Mark May believes Twitter's (TWTR) risk/reward skews to the downside following the recent rally in the shares. A buyout of the company carries "strategic rationale for certain companies," but Twitter's "struggles and steep valuation" make a deal at a meaningful premium less likely, May tells investors in a research note. A takeover at $26 per share looks aggressive, May contends. He believes the stock could retest the lows of late May, representing 40% downside from current levels, should an acquisition offer not materialize. The analyst keeps a Neutral rating on Twitter with a $16 price target. The shares closed yesterday up 75c to $23.37 following reports that Disney (DIS) may be joining the list of potential acquires that already includes Alphabet (GOOG) and Salesforce (CRM).
09/26/16
09/26/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Disney (DIS) downgraded to Hold from Buy at Drexel Hamilton with analyst Tony Wible saying he believes a large step up in NBA costs, incremental subscribers losses, difficult studio comps, a riskier studio slate, and Shanghai cost pressures will weigh on fiscal 2017. 2. Twitter (TWTR) downgraded to Underperform from Perform at Oppenheimer with analyst Jason Helfstein saying a media company is the most likely acquirer of Twitter and would not pay meaningfully more than the valuation implied by our price target. 3. RetailMeNot (SALE) downgraded to Sell from Hold at Stifel with analyst Scott Devitt saying third party data indicates that the company's traffic trends have deteriorated recently. 4. Finish Line (FINL) downgraded to Neutral from Buy at Buckingham with the firm's analyst believing shares will be range bound in medium term due to high comp expectations, cost savings will be offset by incentive compensation and other investments, and less compelling valuation. 5. NetApp (NTAP) downgraded to Sell from Hold at Deutsche Bank with analyst Sherri Scribner saying secular challenges in the storage market are not reflected in NetApp's current valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
CRM Salesforce
$71.08

2.655 (3.88%)

WMT Wal-Mart
$69.96

-1.715 (-2.39%)

09/29/16
KEYB
09/29/16
INITIATION
Target $90
KEYB
Overweight
Wal-Mart initiated with an Overweight, momentum building, says KeyBanc
As previously reported, KeyBanc initiated Wal-Mart with an Overweight and a $90 price target. Analyst Edward Yruma believes Wal-Mart's investments in e-commerce and technology will drive sustainable market share gains and return the company to both consistent revenue and EBITDA growth in 2017.
09/29/16
KEYB
09/29/16
INITIATION
Target $90
KEYB
Overweight
Wal-Mart initiated with an Overweight at KeyBanc
KeyBanc initiated Wal-Mart with an Overweight and a a $90 price target.
09/30/16
GUGG
09/30/16
INITIATION
Target $82
GUGG
Buy
Wal-Mart initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Wal-Mart with a Buy and a $82 price target saying it is successfully adapting to the rapidly changing consumer environment and remains laser focused on improving its critical U.S. supercenter business.
09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AAPL Apple
$113.05

0.05 (0.04%)

10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Apple has positive read through from Dialog results, says RBC Capital
After Dialog issued a positive preannouncement due to higher than expected Mobile Services revenue, RBC Capital analyst Amit Daryanani thinks that the Dialog results should comfort Apple investors heading into that company's September quarter results. The analyst notes that Apple accounts for 75%-80% of Dialog's revenue. He keeps a $125 price target and Outperform rating on Apple.
10/06/16
ADAM
10/06/16
NO CHANGE
Target $140
ADAM
Buy
Apple iPhone 7 demand remains healthy, says Canaccord
Canaccord analyst T. Michael Walkley said channel checks show demand for iPhone 7 remains healthy with an ongoing strong mix leading to higher selling prices. The analyst believes the iPhone 6 and iPhone 6s products enabled Apple to materially increase its market share and installed base of the premium tier smartphone market. Walkley reiterate his Buy rating and $140 price target on Apple shares.
10/05/16
UBSW
10/05/16
NO CHANGE
Target $127
UBSW
Buy
Apple preparing for next era of personal technology, says UBS
UBS analyst Steve Milunovich notes his residual income model for Apple shows only small growth beyond three years. He believes the current share price reflects the slight annual declines but he thinks the cautious view would be incorrect because Apple is preparing for the next era of personal technology. Milunovich calls the next phase the Ambient Paradigm, which will require hardware, software, and orchestration to provide a seamless experience across all consumer devices. The Apple Watch, AirPods, and possibly other wearables will eventually impact industries such as healthcare and education and could be the next scarcity, said Milunovich, who reiterated his Buy rating and $127 price target on Apple shares.
GOOG Alphabet
$776.47

0.04 (0.01%)

09/28/16
MZHO
09/28/16
DOWNGRADE
Target $15
MZHO
Underperform
Mizuho cuts Twitter to Underperform with $15 price target
Mizuho analyst Neil Doshi downgraded Twitter to Underperform from Neutral based on valuation. The shares are up 45% since the company reported Q2 results, primarily driven by potential buyout comments in media reports, Doshi tells investors in a research note. The stock at current levels is overvalued as Twitter's business fundamentals "have deteriorated significantly" over the past 12 months, the analyst contends. Doshi believes many of the M&A scenarios are unlikely to play out. He puts potential acquirers Salesforce (CRM) and Alphabet (GOOG, GOOGL) in the "maybe" camp, but he still has some reservations about these deals happening. The analyst believes investors of both companies would view a buyout of Twitter as negative. Doshi keeps a $15 price target for Twitter shares. The stock closed yesterday up 35c to $23.72. Loop Capital this morning also downgraded Twitter to Sell.
09/27/16
WEDB
09/27/16
DOWNGRADE
WEDB
Underperform
Alphabet downgraded to Underperform from Neutral at Wedbush
Wedbush analyst James Dix downgraded Alphabet to Underperform and lowered his price target on shares to $700 on concerns the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GOOGL Alphabet Class A
$801.23

-1.56 (-0.19%)

09/30/16
RBCM
09/30/16
NO CHANGE
RBCM
Street underestimating Google growth outlook, says RBC Capital
RBC Capital analyst Mark Mahaney expects Google to end 2016 with "up to 20% growth," versus the Street's outlook of mid teen percentage level growth. Mahaney says that Google's growth should be boosted by "ongoing Search innovations, rising Mobile CPCs, and the growing impact of YouTube, Play & Cloud." He thinks that YouTube's revenue is growing at a 30%-40% clip. Mahaney raised his price target on the stock to $1,025 from $1,000 and keeps an Outperform rating on the shares.
YUM Yum! Brands
$87.31

-1.3082 (-1.48%)

09/23/16
09/23/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from Sector Perform by RBC analyst Mark Mahaney, who cut his price target to $14 from $17. The research firm's survey of more than 1,100 advertising professionals and their attitudes towards Facebook (FB), Google (GOOG), Twitter and other high-profile names showed that, despite marketing budgets continuing to shift online, interest in the microblog platform appears to be declining. Of note, Twitter shares have surged this morning after CNBC's David Faber reported that Twitter is moving closer to selling itself and has received expressions of interest in a possible sale, although no deal is imminent. 2. Yum! Brands (YUM) downgraded to Outperform from Top Pick by RBC Capital analyst David Palmer based on valuation. His price target on Yum shares remains $97. 3. Becton Dickinson (BDX) downgraded to Sell from Neutral by Citi analyst Amit Hazan, who thinks a cyclical U.S. slowdown will push the company's organic growth below expectations. The analyst, who also sees a diminishing impact on Becton's growth from emerging markets, cut his price target for the shares to $165 from $167. 4. NextEra Energy (NEE) downgraded to Hold from Buy by Deutsche Bank analyst Jonathan Arnold, as he sees limited near-term upside with the shares up 23% year-to-date. "Extraordinarily frosty commentary" from two of three PUCT commissioners yesterday regarding NextEra's Oncor deal indicates an uphill battle in getting it approved, Arnold tells investors. 5. AVANGRID (AGR) downgraded to Underweight from Neutral by JPMorgan analyst Christopher Turnure, who thinks both the company's growth guidance and consensus expectations "appear ambitious." He lowered his price target for the shares to $41 and $44 and notes he does not have confidence in AVANGRID's near-term growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/16
OPCO
10/06/16
NO CHANGE
Target $97
OPCO
Outperform
Oppenheimer would be aggressive buyer of Yum! Brands below $90
After Yum! Brands reported an in-line earnings quarter, Oppenheimer analyst Brian Bittner remains attracted to the shares ahead of several catalysts. The analyst would be an aggressive buyer of Yum! Brands below $90 per share. He reiterates an Outperform rating and $97 price target on the stock.
09/29/16
BERN
09/29/16
NO CHANGE
BERN
New Yum! poised to benefit from cost cutting, unit growth, says Bernstein
Bernstein analyst Sara Senatore says that New Yum! - the global franchisor of KFC, Pizza Hut, and Taco Bell which will trade separately from the current company's China assets following an upcoming spin off - should benefit from cost cutting and steady unit growth. New Yum! will be able to cut up to $140M+.of costs, and "steady unit growth" should "provide underlying support" for its revenue, she stated. The analyst keeps a $98 price target and Outperform rating on current, combined Yum!.
09/29/16
OPCO
09/29/16
NO CHANGE
Target $97
OPCO
Outperform
Yum! Brands remains a favorite at Oppenheimer
Oppenheimer analyst Brian Bittner says Yum! Brands remains one of his "favorite Outperforms," despite its 23% year-to-date gain. The analyst raised his price target on the stock to $97 from $96, citing his updated sum-of-parts heading into the October 31 separation of the company's China business. Nonetheless, Bittner notes that this does not incorporate additional potential upside from an attractive G&A opportunity, potential for larger than expected capital returns post-separation at both entities, and continued earnings power restoration at Yum China. He reiterates an Outperform rating on the shares.
ZUMZ Zumiez
$18.27

-0.19 (-1.03%)

05/23/16
KEYB
05/23/16
NO CHANGE
KEYB
Some retailers better positioned than others to adopt to trends, says KeyBanc
After attending the Shoptalk conference, KeyBanc says that some retailers are better positioned than others to adopt to changing trends in the sector. Better positioned retailers include those "with compelling experiences," including Nordstrom (JWN), and those "with strong consumers connections," such as Lululemon (LULU), VF Corp (VFC), Oxford Industries (OXM), and Under Armour (UA), according to the firm. Conversely, retailers with large store footprints, particularly those with a significant presence in malls, "will continue to see pressure," KeyBanc believes. Among the companies in the latter category are L Brands (LB), Zumiez (ZUMZ), The Buckle (BKE), and Francesca's (FRAN), according to the firm.
10/06/16
RILY
10/06/16
UPGRADE
Target $25
RILY
Buy
Zumiez upgraded to Buy from Neutral at B. Riley
B. Riley analyst Jeff Van Sinderen upgraded Zumiez to Buy after the company reported better than expected September comps and upped its Q3 outlook. The analyst raised his price target for the shares to $25 from $18.
10/06/16
WBLR
10/06/16
UPGRADE
WBLR
Outperform
Zumiez upgraded to Outperform from Market Perform at William Blair
William Blair analyst Sharon Zackfia upgraded Zumiez to Outperform saying September marked the company's best comp gain since February 2015. B. Riley this morning also upgraded Zumiez.
03/11/16
BMUR
03/11/16
NO CHANGE
Target $24
BMUR
Buy
Zumiez still best-in-class, says Brean Capital
Brean Capital noted Zumiez beat the firm's estimate for Q4 earnings but gave lower than expected guidance for Q1. The firm maintained its Buy rating on Zumiez, and as it considers it "best-in-class," citing its omni-channel investments that will start impacting the top line, easing comps and signs of a pickup in business. Brean Capital maintained its $24 price target on Zumiez shares.
ICUI ICU Medical
$125.96

0.26 (0.21%)

08/09/16
ROTH
08/09/16
NO CHANGE
Target $132
ROTH
Buy
ICU Medical Direct sales momentum continues, says Roth Capital
Roth Capital analyst Chris Lewis says ICU Medical delivered a Q2 beat and raised its 2016 outlook as Direct sales momentum and OEM/Hospira growth continued. Although the company expects an even steeper decline in Hospira over the second half of 2016, the analyst believes ICU Medical is well-positioned to sustain revenue growth on Direct strength and non-Hospira OEM channels, with margin expansion opportunities materializing in 2017. Lewis reiterates a Buy rating on the stock and raised his price target on the shares to $132 from $130.
01/14/16
PIPR
01/14/16
NO CHANGE
Target $129
PIPR
Overweight
Piper views potential Pfizer divestment as neutral for ICU Medical
Piper Jaffray analyst Thomas Gunderson views Bloomberg's report that Pfizer (PFE) may be considering a sale of the infusion pump division of the recently acquired Hospira as neutral for ICU Medical (ICUI). Hospira has traditionally been ICU's largest customer, which has some worrying that if the infusion pumps are sold once again, the business could be at risk, Gunderson tells investors in a research note. He believes, however, that a Pfizer divestment could bring some upside to ICU since the infusion pump business is not in the pharma giant's "wheelhouse." Gunderson keeps an Overweight rating on ICU Medical with a $129 price target.
03/11/16
GABE
03/11/16
INITIATION
GABE
Buy
ICU Medical initiated with a Buy at Gabelli
PFE Pfizer
$33.70

-0.2 (-0.59%)

09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
08/23/16
PIPR
08/23/16
NO CHANGE
PIPR
Pfizer acquisition 'a good fit strategically,' says Piper Jaffray
After Pfizer (PFE) agreed to buy Medivation (MDVN), Piper Jaffray analyst Richard Purkiss says that Pfizer has obtained Xtandi, "a blockbuster prostate cancer treatment," and "a close-to-market and late-stage pipeline." The analyst thinks that Xtandi's expansion to use in adjuvant prostate cancer could increase its sales by 65%-70%. He keeps a $54 price target and Overweight rating on Pfizer.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
ALNY Alnylam
$70.30

1.73 (2.52%)

10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Ionis has no read through from negative Alnylam data, says Wells Fargo
After Ionis (IONS) competitor Alnylam Pharmaceuticals (ALNY) announced that it was terminating the development of its revusiran RNAi drug due to poor outcomes in clinical trials, Wells Fargo thinks that the news is "a significant positive" for Ionis because it eliminates a competitor. The firm says that Ionis' drug is significantly different than Alnylam's product, and it believes that Ionis' treatment appears to be superior. The firm keeps an Outperform rating on Ionis.
10/06/16
COWN
10/06/16
NO CHANGE
Target $100
COWN
Outperform
Alnylam price target lowered to $100 from $150 at Cowen
Cowen analyst Ritu Baral noted Alnylam announced the discontinuation of revusiran for the treatment of hereditary ATTR amyloidosis with cardiomyopathy due to risk/benefit and safety signals. The analyst does not believe it signals any risk to the platform, as other programs have shown solid safety. Baral said revusiran was a minor driver so she maintained her Outperform rating and lowered her price target to $100 from $150 on Alnylam shares.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
MDCO The Medicines Co.
$38.51

0.32 (0.84%)

10/06/16
JEFF
10/06/16
NO CHANGE
Target $43
JEFF
Buy
Alnylam setback has no read-through to Medicines Co., says Jefferies
Jefferies analyst Biren Amin believes Alnylam Pharmaceuticals' (ALNY) decision to stop revusiran due to lack of a treatment benefit has no read-through to The Medicines Co.'s (MDCO) PCSK9 program. Amin keeps a Buy rating on Medicines Co. with a $43 price target.
08/02/16
EVER
08/02/16
NO CHANGE
EVER
Buy
Pfizer shelves oral PCSK9, a Medicines Co. competitor, says Evercore ISI
Evercore ISI analyst Umer Raffat said Pfizer (PFE) management does not thin the profile for oral PCSK9 will be competitive with the strong efficacy of antibodies and have moved other interesting products forward. Raffat said some Medicines Co. (MDCO) investors had worried that a potential oral PCSk9 from Pfizer could greatly reduce enthusiasm for an every-6-month PCSk9 from MDCO. The analyst said the next catalyst for The Medicines Co. is A1 Milano readout this month. Raffat rates The Medicines Co. a Buy with a $52 price target.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
TPC Tutor Perini
$20.39

-1.81 (-8.15%)

10/03/16
STPT
10/03/16
UPGRADE
STPT
Buy
Tutor Perini upgraded to Buy from Hold at Standpoint Research
08/24/16
MKMP
08/24/16
UPGRADE
MKMP
Buy
Tutor Perini upgraded to Buy from Neutral at MKM Partners
07/14/16
ADAM
07/14/16
NO CHANGE
Target $30
ADAM
Buy
Tutor Perini price target raised to $30 from $18 at Canaccord
Canaccord raised its price target on Tutor Perini to $30 from $18 to reflect the potential for upside to estimates from strength in higher margin civil revenues based on strong award activity and a robust bid pipeline. Canaccord reiterated its Buy rating on Tutor Perini shares.
08/24/16
08/24/16
UPGRADE
Target $28

Buy
Tutor Perini upgraded to Buy on debt repayments at MKM Partners
As previously reported, MKM Partners upgraded Tutor Perini to Buy and increased its price target to $28 from $23. Analyst Daniel Scott believes Tutor's plans to reduce uncollected billings are on track and will allow the company to reduce debt meaningfully over the next 18 months, just as earnings momentum from the FAST Act and the $42B project pipeline kicks in.

TODAY'S FREE FLY STORIES

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

17:04
12/02/16
12/02
17:04
12/02/16
17:04
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIR

Osiris

$5.68

0.06 (1.07%)

17:02
12/02/16
12/02
17:02
12/02/16
17:02
Hot Stocks
Osiris: Nasdaq grants company's request for additional time »

Osiris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.